中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
17期
26-29
,共4页
癌,肝细胞%内皮抑制素%动脉化疗栓塞%血管内皮生长因子
癌,肝細胞%內皮抑製素%動脈化療栓塞%血管內皮生長因子
암,간세포%내피억제소%동맥화료전새%혈관내피생장인자
Cancer,liver cells%Endostatin%Arterial chemoembolization%Vascular endothelial growth factor
目的 研究重组人血管内皮抑制素联合肝动脉化疗栓塞(TACE)治疗原发性肝细胞癌(HCC)的效果.方法 选择原发性HCC患者52例,按随机数字表法分为联合组和对照组,每组26例,两组均采用TACE治疗,联合组在栓塞乳剂中加入重组人血管内皮抑制素,对比两组近期有效率、血清血管内皮生长因子(VEGF)水平、不良反应、复发率和生存率.结果 联合组有效率(RR)和疾病控制率(DCR)分别为57.69％(15/26)、84.62％ (22/26),对照组RR和DCR分别为34.62％(9/26)、73.08％(19/26),两组RR(x2=5.237,P＜0.05)和DCR(x2=4.284,P＜ 0.05)比较差异均有统计学意义.TACE术后第7,14,28天,联合组和对照组血清VEGF水平变化呈现先上升后下降的趋势,差异均有统计学意义(P＜0.05),联合组血清VEGF水平显著低于对照组(P＜0.05).随访率94.23％(49/52),联合组术后1,2年复发率均显著低于对照组(P＜0.05),联合组术后2,3年生存率均显著高于对照组(P＜0.05).结论 在TACE术中加用重组人血管内皮抑制素能够有效抑制患者血清VEGF水平上升,提高近期RR和DCR,抑制VEGF可能减少肿瘤近期复发,提高生存率.
目的 研究重組人血管內皮抑製素聯閤肝動脈化療栓塞(TACE)治療原髮性肝細胞癌(HCC)的效果.方法 選擇原髮性HCC患者52例,按隨機數字錶法分為聯閤組和對照組,每組26例,兩組均採用TACE治療,聯閤組在栓塞乳劑中加入重組人血管內皮抑製素,對比兩組近期有效率、血清血管內皮生長因子(VEGF)水平、不良反應、複髮率和生存率.結果 聯閤組有效率(RR)和疾病控製率(DCR)分彆為57.69％(15/26)、84.62％ (22/26),對照組RR和DCR分彆為34.62％(9/26)、73.08％(19/26),兩組RR(x2=5.237,P＜0.05)和DCR(x2=4.284,P＜ 0.05)比較差異均有統計學意義.TACE術後第7,14,28天,聯閤組和對照組血清VEGF水平變化呈現先上升後下降的趨勢,差異均有統計學意義(P＜0.05),聯閤組血清VEGF水平顯著低于對照組(P＜0.05).隨訪率94.23％(49/52),聯閤組術後1,2年複髮率均顯著低于對照組(P＜0.05),聯閤組術後2,3年生存率均顯著高于對照組(P＜0.05).結論 在TACE術中加用重組人血管內皮抑製素能夠有效抑製患者血清VEGF水平上升,提高近期RR和DCR,抑製VEGF可能減少腫瘤近期複髮,提高生存率.
목적 연구중조인혈관내피억제소연합간동맥화료전새(TACE)치료원발성간세포암(HCC)적효과.방법 선택원발성HCC환자52례,안수궤수자표법분위연합조화대조조,매조26례,량조균채용TACE치료,연합조재전새유제중가입중조인혈관내피억제소,대비량조근기유효솔、혈청혈관내피생장인자(VEGF)수평、불량반응、복발솔화생존솔.결과 연합조유효솔(RR)화질병공제솔(DCR)분별위57.69％(15/26)、84.62％ (22/26),대조조RR화DCR분별위34.62％(9/26)、73.08％(19/26),량조RR(x2=5.237,P＜0.05)화DCR(x2=4.284,P＜ 0.05)비교차이균유통계학의의.TACE술후제7,14,28천,연합조화대조조혈청VEGF수평변화정현선상승후하강적추세,차이균유통계학의의(P＜0.05),연합조혈청VEGF수평현저저우대조조(P＜0.05).수방솔94.23％(49/52),연합조술후1,2년복발솔균현저저우대조조(P＜0.05),연합조술후2,3년생존솔균현저고우대조조(P＜0.05).결론 재TACE술중가용중조인혈관내피억제소능구유효억제환자혈청VEGF수평상승,제고근기RR화DCR,억제VEGF가능감소종류근기복발,제고생존솔.
Objective To study the effect of recombinant human endostatin hormone combined with transcatheter arterial chemoembolization (TACE) for the treatment of primary hepatocellular carcinoma (HCC).Methods Fifty-two primary HCC patients were divided into combined group (26 patients) and control group (26 patients) by random digits table method.The patients in combined group received TACE and recombinant human endostatin hormone added in embolism emulsion.The recent curative effect,level of serum vascular endothelial growth factor (VEGF),adverse reactions,recurrence rate and survival rate were compared between two groups.Results The response rate(RR) and clinical benefit rate(DCR) in combined group were 57.69％(15/26),84.62％(22/26),in control group were 34.62％(9/26),73.08％(19/26),there were significant differences (x2 =5.237,P ＜ 0.05 ; x2 =4.284,P ＜ 0.05).The 7th,14th,28th day after TACE,the level of VEGF in two groups was first increased and then a downward trend,the difference were statistically significant (P ＜ 0.05).The level of VEGF in combined group was significantly lower than that in control group (P＜ 0.05).The follow up rate was 94.23％(49/52),the 1-year and 2-year recurrence rate in combined group was significantly lower than that in control group (P＜ 0.05).The 2-year and 3-year survival rate in combined group was significantly higher than that in control group (P ＜ 0.05).Conclusion With TACE plus recombinant human endostatin hormone can effectively inhibit the increase of serum VEGF level,improve curative effect and disease control rate,reduce tumor recurrence and improve survival rate.
